NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/23/2025
Back to search
Official data from USPTO
A2 BIO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
A2 BIO
ST13
US500000097980568Class
5, 40, 42
Filing
97980568
Registration
7961427
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
09/23/2025
Trademark type
Word
Nice classes
5, 40, 42
Filing date
02/15/2023
Registration date
09/23/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/23/2025
Last transaction
09/23/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/01/2023
First use in commerce
05/01/2023
Drawing code
4
Owner type
03
Owner location
Agoura Hills, CA
Examiner
KOLODNER, LOUIS
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
A2 Biotherapeutics, Inc.
Representatives
Joi A. White CARR & FERRELL LLP
Technical classification
Nice Classes
Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Therapeutics in the nature of cellsproteins and protein complexes for the treatment and prevention of cancer; biotherapeutics for the treatment and prevention of cancer; medicines for the treatment and prevention of cancer; pharmaceutical products for the treatment and prevention of cancer; therapeutic targetsproteins or protein complexesfor the treatment and prevention of cancer; therapeutic cellstherapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer; therapeutics and cell therapies in the nature of cellsproteins and protein complexes for the treatment of cancer; engineered cell therapies in the nature of cellsproteins and protein complexes for medical purposesthe treatment and prevention of cancer; engineered cell therapy platforms consisting of modified cellscell receptorsproteins and protein complexes; cell platforms consisting of modified cellscell receptorsproteins and protein complexes for the treatment and prevention of cancer; technology platforms for developing and engineering therapeutic cellstherapeutic proteinstherapeutic antibodiestherapeutics and cellular therapies for the treatment and prevention of cancer; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; gene therapy productsgenetically engineered tissues for transplant purposes
Class 40
Custom manufacturing of therapeuticsbiotherapeuticsmedicinespharmaceuticals; manufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancer; biomanufacturing for othersmanufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancer using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cellscellular targetsproteinsantibodies for others for treatment and prevention of cancer
Class 42
Medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeuticsbiotherapeuticsmedicinespharmaceuticals; identification and development of therapeutic targets for others for the treatment and prevention of cancer; development of therapeutics and cell therapies for treatment and prevention of cancer; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; biotechnology researchdevelopmenttesting and analysis for the treatment of cancer; scientific research and development services; providing scientific information relating to treatment and prevention of cancer; researchdevelopmentengineering and testing services in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; medical laboratory servicestissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services
Publications
History of USPTO decisions and trademark events.
35 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/23/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/03/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/03/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/26/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/25/2025
EX3G
SOU EXTENSION 3 GRANTED
08/25/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
08/25/2025
EEXT
SOU TEAS EXTENSION RECEIVED
08/12/2025
EXT3
SOU EXTENSION 3 FILED
08/11/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/11/2025
IUAF
USE AMENDMENT FILED
05/08/2025
DRRR
DIVISIONAL REQUEST RECEIVED
05/08/2025
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
05/08/2025
EISU
TEAS STATEMENT OF USE RECEIVED
05/08/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/20/2025
EX2G
SOU EXTENSION 2 GRANTED
02/20/2025
EXT2
SOU EXTENSION 2 FILED
02/19/2025
EEXT
SOU TEAS EXTENSION RECEIVED
02/19/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/19/2024
EX1G
SOU EXTENSION 1 GRANTED
08/19/2024
EXT1
SOU EXTENSION 1 FILED
08/19/2024
EEXT
SOU TEAS EXTENSION RECEIVED
08/19/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/20/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/26/2023
PUBO
PUBLISHED FOR OPPOSITION
12/26/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/06/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/17/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
11/17/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/17/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
11/17/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/17/2023
DOCK
ASSIGNED TO EXAMINER
11/14/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/06/2023
NWAP
NEW APPLICATION ENTERED
02/18/2023
Continuous trademark protection
Get notified about every new filing that threatens A2 BIO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.